title: Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
abstract: The purpose of our study was to determine the efficacy of 2-chlorodeoxyadenosine (2-CdA) administered in 2-hour intravenous infusions in previously treated patients with low grade non-Hodgkin's lymphoma (LGNHL). We treated 94 LGNHL patients with 2-CdA at a dosage of 0.12 mg/kg/24h in 2-hour intravenous infusion for 5 consecutive days. The treatment consisted of from 1 to 7 courses (median 3), repeated usually at monthly intervals. All patients were refractory to or relapsed after standard chemotherapy. Of these 94 patients 78 (83%) had clinical stage IV of the disease. Complete response (CR) was obtained in 12 (12.8%) and partial response (PR) in 36 (38.3%) giving an overall response rate of 51.1%. In 12 (12.8%) grade 4 thrombocytopenia with haemorrhagic diathesis was noted, grade 4 neutropenia was observed in 12 (12.8%) and infections complicated the course of treatment in 38 (40.4%) patients. 2-CdA treatment was the cause of death of 3 patients. The results of our study show that 2-CdA given in 2-hour infusions is an effective agent in advanced, heavily pretreated patients with LGNHL.
authors.affiliation: Department of Hematology, Medical University of Lódź, Poland.
authors.forename: T
authors.initials: T
authors.lastname: Róbak
authors.forename: J
authors.initials: J
authors.lastname: Gora-Tybor
authors.forename: E
authors.initials: E
authors.lastname: Krykowski
authors.forename: J A
authors.initials: JA
authors.lastname: Walewski
authors.forename: A
authors.initials: A
authors.lastname: Borawska
authors.forename: A
authors.initials: A
authors.lastname: Pluźańska
authors.forename: P
authors.initials: P
authors.lastname: Potemski
authors.forename: A
authors.initials: A
authors.lastname: Hellmann
authors.forename: J M
authors.initials: JM
authors.lastname: Zaucha
authors.forename: L
authors.initials: L
authors.lastname: Konopka
authors.forename: B
authors.initials: B
authors.lastname: Ceglarek
authors.forename: T
authors.initials: T
authors.lastname: Durźyński
authors.forename: A
authors.initials: A
authors.lastname: Sikorska
authors.forename: K
authors.initials: K
authors.lastname: Michalak
authors.forename: J
authors.initials: J
authors.lastname: Urasiński
authors.forename: J
authors.initials: J
authors.lastname: Opalińska
authors.forename: A
authors.initials: A
authors.lastname: Dmoszyńska
authors.forename: M B
authors.initials: MB
authors.lastname: Adamczyk-Cioch
authors.forename: Z
authors.initials: Z
authors.lastname: Kuratowska
authors.forename: J
authors.initials: J
authors.lastname: Dwilewicz-Trojaczek
authors.forename: P
authors.initials: P
authors.lastname: Boguradzki
authors.forename: M
authors.initials: M
authors.lastname: Deren
authors.forename: S
authors.initials: S
authors.lastname: Maj
authors.forename: P
authors.initials: P
authors.lastname: Grieb
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017338:Cladribine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D019233:Retreatment
chemical_list: D000970:Antineoplastic Agents; D017338:Cladribine